EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA authorised Sacituzumab govitecan (Trodelvy) for breast cancer, including triple-negative breast cancer, on 5 June 2025, with Gilead Sciences Ireland UC as t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Triple Negative Breast Neoplasms. MAH: Gilead Sciences Ireland UC. Decision date: 05/06/2025